Department of General Surgery Thyroid Specialty, The Second Xiangya Hospital of Central South University, Changsha, China.
Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
Front Endocrinol (Lausanne). 2022 Feb 24;13:801925. doi: 10.3389/fendo.2022.801925. eCollection 2022.
The prevalence of thyroid carcinoma (TC) and Hashimoto's thyroiditis (HT) has been increasing dramatically over the past decades. We investigated the relationship between HT and TC.
We followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines for carrying out and reporting this meta-analysis. The literature from January 1, 2010 to December 31, 2020, regardless of region and publication type, was searched comprehensively in PubMed, Embase, Web of Science, and Cochrane Library databases. After careful selection and data extraction, the pooled odds ratio of various clinical characteristics in 39 studies were calculated. Publication bias was analyzed using funnel plots.
Meta-analysis of 39 original research articles showed HT to be a risk factor of TC (pooled odds ratio = 1.71; 95% confidence interval, 1.57-1.80; 0.00001) and papillary thyroid carcinoma (1.67, 1.51-1.85, <0.00001). Patients with papillary thyroid carcinoma (PTC) combined with HT were more likely to have multifocal carcinomas. The prevalence of an extrathyroidal extension, metastasis, BRAF mutation, and recurrence was significantly lower in patients with PTC combined with HT.
HT is a "double-edged sword" in TC patients. HT increases the risk of TC and PTC but is a protective factor against PTC progression.
在过去几十年中，甲状腺癌（TC）和桥本甲状腺炎（HT）的患病率显著增加。我们研究了 HT 与 TC 之间的关系。
我们遵循观察性研究的荟萃分析（MOOSE）指南进行和报告这项荟萃分析。全面检索了 2010 年 1 月 1 日至 2020 年 12 月 31 日PubMed、Embase、Web of Science 和 Cochrane Library 数据库中的文献，无论地域和出版类型如何。经过仔细筛选和数据提取，计算了 39 项研究中各种临床特征的汇总优势比。使用漏斗图分析发表偏倚。
对 39 项原始研究的荟萃分析表明，HT 是 TC（汇总优势比=1.71；95%置信区间，1.57-1.80；0.00001）和甲状腺乳头状癌（1.67，1.51-1.85，<0.00001）的危险因素。甲状腺乳头状癌（PTC）合并 HT 的患者更容易发生多灶性癌。PTC 合并 HT 的患者发生甲状腺外延伸、转移、BRAF 突变和复发的比例明显较低。
HT 是 TC 患者的“双刃剑”。HT 增加了 TC 和 PTC 的风险，但却是 PTC 进展的保护因素。
